Diatos S.A. Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
6/4/2007 12:25:20 PM
PARIS--(BUSINESS WIRE)--Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, today announced that they presented data from a Phase I clinical trial of their anti-cancer compound, DTS-201, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA.
comments powered by